CIGB 50

Drug Profile

CIGB 50

Alternative Names: Anti-IL-15-vaccine-CIGB; Anti-interleukin-15-vaccine-CIGB; CIGB50

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Vaccines
  • Mechanism of Action Advanced glycosylation end product modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 24 Feb 2016 Phase-I clinical trials in Rheumatoid arthritis in Cuba (SC) prior to February 2016 (CIGB-Heber Biotech pipeline, February 2016)
  • 31 Dec 2015 Immunogenicity data from a preclinical trial released by CIGB (CIGB-Heber Biotech presentation, 2014-2015)
  • 31 Dec 2013 Preclinical trials in Rheumatoid arthritis in Cuba (SC) (CIGB presentation,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top